Impact of SGLT-2i on Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Pooled result · COPD exacerbationsResult — go to the resultPooled hazard ratio 0.646 95 % CI 0.470–0.889Authors' conclusion
SGLT-2 inhibitors significantly reduce COPD exacerbations in T2DM patients, offering dual benefits in managing both glycemic control and respiratory health. These findings support the integration of SGLT-2 inhibitors into treatment regimens for T2DM-COPD overlap. Further randomized controlled trials and long-term studies are needed to confirm the lasting efficacy and explore the underlying mechanisms.
Study context
- Population
- Patients with T2D (T2D–COPD); studies published until March 2025, PubMed, Embase, Web of Science
- Comparison
- SGLT2i vs other antidiabetic agents
- Outcome
- COPD exacerbations
Methodological detailsPRISMA guidelines
- PRISMA guidelines
Pooled result
As reported in the abstract
Pooled hazard ratio
0.646
95 % CI 0.470–0.889
SGLT-2ivs Other antidiabetic agents
pooled HR 0.646 (95 % CI 0.470–0.889)
Further pooled results
| Outcome | HR (95 % CI) | |
|---|---|---|
| COPD exacerbations, SGLT2ivs SU | 0.620 (0.526–0.731) | |
| 0.512Hazard ratio (log scale) |
Severe COPD exacerbations
- Reduction in severe exacerbations not statistically significant
- HR: 0.715, 95 % CI: 0.403-1.269
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Impact of SGLT-2i on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab. Published 11 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →